Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded at BidaskClub
A number of other equities analysts have also recently issued reports on CPRX. Zacks Investment Research cut shares of HENGAN INTL GRP/ADR from a strong-buy rating to a hold rating in a report on Tuesday, May 21st. ValuEngine cut Valero Energy from a hold rating to a sell rating in a report on Wednesday, May 8th. Cantor Fitzgerald reaffirmed a buy rating and set a $15.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, May 7th. Finally, HC Wainwright set a $25.00 price target on Onconova Therapeutics and gave the company a buy rating in a report on Tuesday, May 14th. Seven investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus target price of $7.35.
Shares of NASDAQ CPRX opened at $4.07 on Thursday. The company has a quick ratio of 6.07, a current ratio of 6.08 and a debt-to-equity ratio of 0.02. The stock has a 50-day simple moving average of $3.70. Catalyst Pharmaceuticals has a 52-week low of $1.85 and a 52-week high of $6.16. The company has a market capitalization of $418.62 million, a PE ratio of -12.33 and a beta of 2.60.
In other Catalyst Pharmaceuticals news, CEO Patrick J. Mcenany purchased 25,000 shares of the business’s stock in a transaction dated Tuesday, June 11th. The shares were bought at an average price of $3.23 per share, with a total value of $80,750.00. Following the completion of the acquisition, the chief executive officer now owns 4,762,693 shares in the company, valued at approximately $15,383,498.39. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.70% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $28,000. Paloma Partners Management Co acquired a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at approximately $30,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Catalyst Pharmaceuticals by 291.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 27,253 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 20,297 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Catalyst Pharmaceuticals by 18.3% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 36,700 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 5,688 shares during the period. Finally, Biltmore Capital Advisors LLC acquired a new position in shares of Catalyst Pharmaceuticals during the first quarter valued at approximately $79,000. 59.79% of the stock is currently owned by institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Article: Trading Ex-Dividend Strategy
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.